"id","uuid:ID","rationale","instanceType","versionIdentifier"
"StudyVersion_1","486bcb2c-7d74-4414-8e0e-6d47036627b1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","2"
